{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008196","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.296611+00:00","generated_at":"2026-05-15T23:33:10.303861+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Propanc Biopharma board changes: Kenyon retires, Brandt appointed","bullets":["Dr. Julian Kenyon retired from Board on Feb 20, 2026; remains as medical advisor.","Dr. Ralf Brandt appointed to Board same day; 30+ yrs pharma/oncology experience.","Brandt to receive $45,000 annual compensation under Director Agreement.","Brandt has served as CEO of vivoPharm and held exec roles at Novartis and Bionomics."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008196","json":"https://secwatch.observer/filing/0001493152-26-008196.json","markdown":"https://secwatch.observer/filing/0001493152-26-008196.md","text":"https://secwatch.observer/filing/0001493152-26-008196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315226008196/0001493152-26-008196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315226008196/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:33:10.303861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}